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Abstract
Western equine encephalitis virus (WEEV) is a positive-sense, single-stranded RNA virus which is transmitted to equines and humans through
mosquito bites. WEEV infects the central nervous system with severe complications and even death. There are no human vaccine and antiviral
drugs. We investigated whether adenovirus-mediated expression of interferon alpha could be used for pre- and post-exposure protection against a
lethal WEEV challenge in mice. A human adenoviral vector (Ad5-mIFNα) expressing mouse interferon alpha was constructed. We found that
Ad5-mIFNα provided 100% protection against various WEEV strains in mice after a single intramuscular inoculation at 24 h, 48 h or 1 week
before the challenge. When given as a single inoculation at 6 h after the challenge, Ad5-mIFNα delayed the progress of WEEV infection and
provided about 60% protection. Our findings suggest that adenovirus-mediated expression of interferon alpha can be an alternative approach for
the prevention and treatment of WEEV infection.
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Western equine encephalitis virus (WEEV) belongs to the
Alphavirus genus in the Togaviridae family. The virus is
maintained in nature through a cycle involving wild birds as
reservoir hosts and Culex tarsalis mosquitoes as vectors.
Humans and equines are infected by WEEV through mosquito
bites. WEEV causes the central nervous system infection with
signs and symptoms ranging from mild flu-like illness to
neurological signs such as delirium, disorientation, and coma.
The overall case fatality rate is 3%, but increases to 8% in older
adults (Griffin, 2001). Additionally, WEEV can be easily
transmitted through the aerosol route with high mortality rate
(Hanson et al., 1967; Reed et al., 2005).⁎ Corresponding author. Fax: +1 403 544 3388.
E-mail address: josh.wu@drdc-rddc.gc.ca (J.Q.H. Wu).
1 Present address: University of British Columbia, 2329 West Mall,
Vancouver, BC, Canada V6T 1Z4.
0042-6822/$ - see front matter. Crown Copyright © 2007 Published by Elsevier In
doi:10.1016/j.virol.2007.07.024Neither human vaccine nor antiviral drugs are available for
the prevention and treatment of WEEV infection. Several
vaccine candidates have been developed against WEEV. A
formalin-inactivated vaccine under Investigational New Drug
status is available only for laboratory workers at risk of
contracting WEEV (Hoke, 2005). The vaccine is safe but has
poor immunogenicity, which requires three immunizations and
annual boosts to be effective (Smith et al., 1997). A DNA
vaccine candidate completely protects mice against WEEV
(Nagata et al., 2005). However, similar to the formalin-
inactivated vaccine, three immunizations are required to achieve
protection. Live-attenuated WEEV vaccine candidates rapidly
protect animals against WEEV (Schoepp et al., 2002; Turell et
al., 2003). The major obstacle for using the live-attenuated
vaccines in humans is the potential reversion of live-attenuated
virus to virulent WEEV. Therefore, a new approach is needed
for the development of medical countermeasures againstWEEV.
Interferon alpha (IFN-α) is a broad-spectrum antiviral
protein secreted by cells when they sense virus infection
(Garcia-Sastre and Biron, 2006). Currently, the combination ofc. All rights reserved.
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chronic hepatitis C virus infection (Feld and Hoofnagle, 2005).
IFN-α also plays an important role in the control of alphavirus
infection. Grieder and Vogel have demonstrated that mice
lacking the receptor for IFN-α are highly susceptible to the
infection by Venezuelan equine encephalitis virus (VEEV)
(Grieder and Vogel, 1999), a virus that is genetically related to
WEEV. However, the use of IFN-α for the prevention and
treatment of alphavirus infection is hampered by the short half-
life of IFN-α. For example, daily injections with a large dose of
IFN-α are needed to protect animals from a lethal challenge
with WEEV (Julander et al., 2007). Conjugation of IFN-α with
polyethylene glycol extends the half-life and improves the
therapeutic effect of IFN-α. Lukaszewski and Brooks found that
pegylated IFN-α protects mice against VEEV challenge when
given before exposure to the virus whereas unpegylated IFN-α
does not (Lukaszewski and Brooks, 2000).
An alternative strategy for improving the half-life and the
therapeutic effect of IFN-α is the delivery and expression of an
IFN-α gene by a human adenovirus vector (HAdV) (Chinsan-
garam et al., 2003; Demers et al., 2002). HAdV-mediated
expression of IFN-α significantly improves the therapeutic
effect of IFN-α. As an example, a single injection of HAdV
expressing IFN-α is enough to offer rapid pre-exposure
protection against Foot-and-mouth disease virus (Chinsan-Fig. 1. Characterization of Ad5-mIFNα. (A) Schematic diagram of Ad5-mIFNα. PC
signal of Simian virus 40. ΔE1 and ΔE3: the deletions of the E1 and E3 coding reg
detection of the mIFN-α gene are shown as filled black arrows. (B) Detection of the
from Ad5-mIFNα (lane 2) and Ad5-EGFP (lane 3). PCR products were analyzed on a
from cells inoculated with Ad5-mIFNα. Supernatants were collected from mock, Ad
were separated by SDS–PAGE and probed with a rabbit polyclonal antibody specif
recombinant mIFN-α (Calbiochem); lanes 3, 5, and 7: supernatants collected from ce
48 h after inoculation.garam et al., 2003). In this study, we explored whether HAdV-
mediated expression of IFN-α would provide pre- and post-
exposure protection against WEEV.
Results
Characterization of Ad5-mIFNα
To test whether HAdV-mediated expression of IFN-α would
protect mice against WEEV, we constructed a replication-
deficient HAdV (Ad5-mIFNα) expressing mouse IFN-α
(mIFN-α). An infectious plasmid, pAd5-mIFNα, was con-
structed using the AdEasy™ system (He et al., 1998). Ad5-
mIFNα was isolated by day 5 after the transfection of HEK293
cells with pAd5-mIFNα. As shown in Fig. 1A, an expression
cassette was inserted into the deleted E1 region of Ad5-mIFNα
genome. The cassette contains the immediate-early promoter of
cytomegalovirus, an mIFN-α gene and the polyadenylation
signal of Simian virus 40. The mIFN-α gene encodes a signal
peptide of 23 amino acids followed by 166 amino acid residues
(Van Pesch et al., 2004). The signal peptide leads the secretion
of mIFN-α and is subsequently cleaved. PCR was used to verify
the presence of the mIFN-α gene in Ad5-mIFNα. As shown in
Fig. 1B, a 569-bp amplicon was amplified from Ad5-mIFNα
(lane 2). The size of the amplicon agrees with the size of theMV: the immediate-early promoter of cytomegalovirus. PA: the polyadenylation
ions of HAdV to render Ad5-mIFNα replication deficient. PCR primers for the
mIFN-α gene in Ad5-mIFNα. PCR was carried out for the viral DNA extracted
0.8% agarose gel. Lane 1, 1 kb DNA Ladder (Sigma). (C) Secretion of mIFN-α
5-EGFP- or Ad5-mIFNα-inoculated HEK293 cells. Proteins in the supernatants
ic for mIFN-α. Lane 1: MultiMark Multi-colored standard (Invitrogen); lane 2:
lls at 24 h after inoculation; lanes 4, 6, and 8: supernatants collected from cells at
Table 1
Production of mIFN-α in mice inoculated with Ad5-mIFNα
Time post-inoculation Serum mIFN-α
(mean pg/ml±SD, 6 mice per group)
Ad5-mIFNα Ad5-EGFP
6 h 1513±81 0±0
15 h 1687±99 0±0
24 h 987±110 0±0
48 h 1180±60 0±0
1 week 0±0 0±0
13 weeks 0±0 0±0
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amplified from a control vector Ad5-EGFP (lane 3). These
results suggest that Ad5-mIFNα contains the mIFN-α gene.
The secretion of mIFN-α from Ad5-mIFNα was detected by
Western immunoblot using a polyclonal antibody specific for
mIFN-α. Fig. 1C shows that a protein band with a molecular
mass of around 24 kDa appeared in supernatants collected from
HEK293 cells at 24 h (lane 7) and 48 h (lane 8) after Ad5-
mIFNα inoculation. No such band was present in supernatants
collected from mock and Ad5-EGFP-infected cells. These
results confirm that Ad5-mIFNα expresses mIFN-α. In
addition, as indicated in Fig. 1C, the molecular mass of
mIFN-α expressed from HEK293 cells inoculated with Ad5-
mIFNα is slightly larger than that of the recombinant mIFN-α
expressed in Escherichia coli (lane 2). The larger molecular
mass of mIFN-α from HEK293 may be related to the
glycosylation of mIFN-α (Van Pesch et al., 2004).
The antiviral activity of Ad5-mIFNα was determined by its
ability to inhibit VEEV replication. L929 cells were inoculated
with Ad5-mIFNα or Ad5-EGFP at a multiplicity of infection
(MOI) of 5. At 24 h after inoculation, cells were infected with
the TC-83 strain of VEEV at an MOI of 0.1 or 0.5. At 48 h after
infection, the yield of TC-83 in supernatants was measured by
plaque assay in Vero cells. Fig. 2 shows that at both infectious
doses, the TC-83 yield from the L929 cells that were pre-treated
with Ad5-mIFNα was about 4-log less than that from mock or
Ad5-EGFP-pre-treated L929 cells. The result suggests that cells
inoculated with Ad5-mIFNα inhibit VEEV replication.
Production of mIFN-α in mice inoculated with Ad5-mIFNα
We next measured serum mIFN-α in mice after a single
inoculation with Ad5-mIFNα. Mice were each injected
intramuscularly (IM) with 107 plaque-forming units (PFU) of
Ad5-mIFNα. Serum was collected at different time points afterFig. 2. Inhibition of VEEV replication in cells inoculated with Ad5-mIFNα.
L929 cells were inoculated in triplicate with Ad5-mIFNα or Ad5-EGFP. At 24 h
after inoculation, the cells were infected with the TC-83 strain of VEEV at an
MOI of 0.1 or 0.5. The yield of TC-83 in supernatants at 48 h after infection
was determined by plaque assay in Vero cells. Data are presented as mean virus
titers±standard deviations of the mean. ∗Pb0.05 comparing the Ad5-mIFNα-
inoculated cells to mock. §Pb0.05 comparing the Ad5-mIFNα- to Ad5-EGFP-
inoculated cells.injection and measured for the concentration of mIFN-α. A
high-level of mIFN-αwas detected as early as 6 h after injection
and maintained for at least 48 h (Table 1). However, the
production of mIFN-α lasted less than 1 week. No mIFN-α was
produced in mice injected with the control vector Ad5-EGFP.
These data demonstrate that a single inoculation of mice with
Ad5-mIFNα is enough to rapidly produce a large amount of
mIFN-α.
Pre-exposure protection conferred by Ad5-mIFNα
Having demonstrated that mIFN-α is produced from mice
inoculated with Ad5-mIFNα, we investigated whether the
production of mIFN-α in mice would provide pre-exposure
protection against a lethal dose challenge with WEEV. To test
this, mice were each injected IM with 107 PFU of Ad5-mIFNα
or Ad5-EGFP. At different time points after injection, mice were
each challenged intranasally (IN) with 1.5×103 PFU of a low-
virulent WEEV strain (71V-1658 or CBA87) or a high-virulent
WEEV strain (Fleming) (Nagata et al., 2006). Mice that were
challenged with low- or high-virulent WEEV at 24 h, 48 h, and
1 week after Ad5-mIFNα injection were all protected with no
signs of infection (Table 2). In contrast, all the mice given Ad5-
EGFP died with signs of severe infection which developed as
early as day 4 post-challenge (p.c.). When mice were challengedTable 2















24 h p.i. a Fleming 100 (6/6) 0 (0/6) 0.0±0.0 2.3±1.5
(on day 4 p.c.) b
48 h p.i. 71V-
1658
100 (8/8) 0 (0/8) 0.0±0.0 1.5±0.5





100 (8/8) 0 (0/8) 0.0±0.0 3.0±0.5
(on day 9 p.c.)
CBA87 100 (6/6) 0 (0/6) 0.0±0.0 1.8±1.2
(on day 6 p.c.)
13 weeks
p.i.
Fleming 38 (3/8) c 0 (0/8) 0.0±0.0 3.0±0.8
(on day 4 p.c.)
a p.i., post-inoculation with Ad5-mIFNα or Ad5-EGFP.
b p.c., post-challenge with WEEV.
c PN0.05 comparing the Ad5-mIFNα- to Ad5-EGFP-inoculated mice.
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three out of eight mice survived (Table 2). Nevertheless, all the
mice challenged at 13 weeks after Ad5-mIFNα inoculation did
not develop any signs of infection until day 4 p.c., whereas the
mice given Ad5-EGFP were terminally ill at this time (Table 2),
suggesting that Ad5-mIFNα delays the progress of WEEV
infection. Taken together, these data reveal that a single dose of
Ad5-mIFNα provides rapid and long-lasting protection against
lethal challenges of various WEEV strains when given before
exposure to the virus.
Post-exposure protection conferred by Ad5-mIFNα
Finally, we determined whether Ad5-mIFNα would protect
mice against WEEV when given after exposure to the virus.
Mice were each challenged IN with 1.5×103 PFU of Fleming.
At 6 h after challenge, each mouse was injected IM with
107 PFU of Ad5-mIFNα, 107 PFU of Ad5-EGFP or PBS. Five
out of eight mice (about 60%) injected with Ad5-mIFNα
survived (Fig. 3A). In contrast, all the mice given Ad5-EGFP orFig. 3. Post-exposure protection against WEEV after a single inoculation with
Ad5-mIFNα. BALB/c mice (8 mice per group) were each challenged IN with
1.5×103 PFU of WEEV Fleming strain. At 6 h after challenge, mice were each
inoculated IM with 107 PFU of Ad5-mIFNα, 107 PFU of Ad5-EGFP or PBS.
The inoculated mice were monitored for survival (A) and the severity of WEEV
infection (B). ∗Pb0.05 comparing the Ad5-mIFNα- to Ad5-EGFP-inoculated
mice. §Pb0.05 comparing the Ad5-mIFNα- to PBS-inoculated mice.PBS died. The difference in survival rates between the Ad5-
mIFNα-inoculated group and Ad5-EGFP or PBS controls is
statistically significant (Pb0.05). Among the five surviving
mice, four remained healthy by day 14 p.c. and one developed
mild infection by day 10 p.c. Furthermore, all the mice injected
with Ad5-mIFNα did not have any signs of infection by day
4 p.c. (Fig. 3B) whereas mice given Ad5-EGFP or PBS
developed serious disease, indicating that post-exposure
inoculation with Ad5-mIFNα delays the progress of WEEV
infection. We conclude that a single inoculation of Ad5-mIFNα
given after exposure to the virus provides partial protection
against the lethal challenge of WEEV.
Discussion
In this study, we demonstrate that HAdV-mediated expres-
sion of mIFN-α provides both pre- and post-exposure
protection against the lethal challenge of WEEV in mice. We
found that mice were 100% protected when challenged with
various strains of WEEV at 24 h, 48 h or 1 week after a single
inoculation with Ad5-mIFNα (Table 2). The rapid pre-exposure
protection offered by Ad5-mIFNα is similar to that reported in
studies on Foot-and-mouth disease virus (Chinsangaram et al.,
2003; Moraes et al., 2007). We also found that three out of eight
mice (less than 40%) survived when challenged at 13 weeks
after Ad5-mIFNα inoculation although the progress of WEEV
infection in these mice was delayed. This finding suggests that
the protection provided by Ad5-mIFNα is long-lasting.
Furthermore, mice given Ad5-mIFNα at 6 h after WEEV
challenge had a delay in the progress of WEEV infection and
five out of eight mice (about 60%) survived (Fig. 3). The result
of post-exposure protection indicates that HAdV-mediated
expression of IFN-α has potential to be used as a novel
approach for the prevention of alphavirus infection after
exposure to alphaviruses. The current approach towards post-
exposure protection against alphavirus infection is focused on
the passive transfer of protective antibody (Hunt et al., 2006;
Long et al., 2001; Phillpotts et al., 2002). This approach requires
the preparation of a large number of different antibodies specific
for each alphavirus and the identification of the virus before a
protective antibody specific for the virus can be used
(Casadevall, 2002). HAdV-mediated expression of IFN-α
could overcome these limitations. This study shows that
HAdV-mediated expression of IFN-α is effective against
various strains of WEEV (Table 2). Additionally, HAdV-
mediated expression of IFN-α could provide post-exposure
protection against other alphaviruses such as VEEV and Eastern
equine encephalitis virus since these viruses are closely related
to WEEV.
HAdV-mediated expression of IFN-α has several advan-
tages. First, HAdV is relatively safe for human use (Catanzaro et
al., 2006). Second, HAdV transiently expresses IFN-α (Table
1), which allows IFN-α to return to a base level after viruses are
eliminated from the body. The transient expression of IFN-α by
HAdV may reduce side-effects of IFN-α that are often seen in
patients when they are given a long-term, multiple-dose
injection of IFN-α (Feld and Hoofnagle, 2005). Third, HAdV
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expression. Finally, it is relatively easy to produce HAdV in
large quantities.
On the other hand, the disadvantage of HAdV-mediated
expression of IFN-α is preexisting immunity against HAdV in
the human population (Kostense et al., 2004; Vogels et al.,
2003). Preexisting immunity could neutralize HAdV, reducing
the production of IFN-α by the vector. This obstacle can be
overcome by the use of adenovirus vectors derived from
nonhuman adenoviruses (Kobinger et al., 2006; Zakhartchouk
et al., 1998) or human adenovirus serotypes other than serotype
5 (Vogels et al., 2003) which was used in this study for the
construction of Ad5-mIFNα. Additionally, capsid proteins of
HAdV that are the major targets for preexisting immunity
(Sumida et al., 2005) can be modified to evade anti-HAdV
immunity (Roberts et al., 2006).
We found that the production of mIFN-α in mice reached a
peak level by 6 h after a single inoculation with Ad5-mIFNα
(Table 1). This is similar to that observed in rabbits after
injection with an HAdV expressing IFN-α (Demers et al.,
2002). In contrast to the long-term production of IFN-α (up to
40 days) that is found in rabbits, the production of mIFN-α in
our study is transient (less than 1 week) (Table 1). The long-
term production of IFN-α in rabbits could have resulted from
intravenous injection with a larger dose of the HAdV
encoding IFN-α (Demers et al., 2002). A previous study
has shown that the HAdV encoding a gene that is unrelated to
IFN-α triggers the production of IFN-α in both mice and
humans (Huarte et al., 2006). In this study, however, we could
not detect serum mIFN-α in mice given Ad5-EGFP that
encodes the enhanced green fluorescent protein (EGFP) (Table
1). We speculate that the serum mIFN-α produced in Ad5-
EGFP-inoculated mice may be too low to be detected by our
ELISA assay.
The peak production of mIFN-α at 24 h and 48 h after Ad5-
mIFNα inoculation is correlated to the protection of mice
againstWEEV (Tables 1 and 2). On the other hand, although no
serum mIFN-α was detected by 1 week after Ad5-mIFNα
inoculation, mice were completely protected. Similarly, serum
mIFN-α was no longer detectable by 13 weeks after inoculation
with Ad5-mIFNα; However, three out of eight mice survived
and even the mice that died had a delay in the development of
WEEV infection. A possible explanation for the discrepancy
between serum mIFN-α and the protection could be that the
level of mIFN-α in the brain remains high enough to provide
protection while serum mIFN-α wanes. Previous studies have
shown that HAdV enters the brain through traveling up the
olfactory nerves to express therapeutic proteins in neurons
(Davidson and Bohn, 1997; Venkatraman et al., 2005; Zhao et
al., 1996). Therefore, it is likely that mIFN-α could be produced
in the mouse brain after inoculation with Ad5-mIFNα. We
believe that the expression of mIFN-α by Ad5-mIFNα in the
brain is critical for the protection against WEEV because the
brain appears to be the only organ infected by WEEV after
intranasal infection (Reed et al., 2005). Future experiments will
be conducted to determine the expression of mIFN-α in mouse
brain after Ad5-mIFNα inoculation.In contrast to complete pre-exposure protection, partial
protection was obtained in the mice given Ad5-mIFNα at 6 h
after WEEV challenge (Fig. 3). It is probably difficult to
achieve a complete post-exposure protection by Ad5-mIFNα
inoculation because of IFN-α antagonizing proteins produced
by alphaviruses (Aguilar et al., 2007; Garmashova et al.,
2007). These proteins could reduce the efficacy of Ad5-
mIFNα if Ad5-mIFNα is given at several hours after WEEV
infection. Therefore, it is likely that Ad5-mIFNα would pro-
vide better post-exposure protection if given right after WEEV
challenge. In addition, post-exposure protection might be
improved by the simultaneous injection of Ad5-mIFNα with
an HAdV expressing mouse IFN-γ. A recent study demon-
strates that a combination of an HAdVexpressing porcine IFN-
α and an HAdV expressing porcine IFN-γ enhances antiviral
activity against Foot-and-mouth disease virus (Moraes et al.,
2007).
Due to the limitation of this study, we do not know whether
the replication of WEEV is completely blocked in the mice that
had no signs of WEEV infection (Table 2). Further experiments
will be conducted to determine whether viremia and antibodies
specific for the nonstructural proteins of WEEV are present in
these mice. Another limitation is that we defined our challenge
doses of WEEV by using PFU rather than LD50. We will
determine the LD50 of variousWEEV strains to more accurately
evaluate the efficacy of Ad5-mIFNα.
In conclusion, this proof-of-concept study demonstrates that
an HAdV expressing mIFN-α provides rapid protection against
various WEEV strains when given either before or after
exposure to WEEV. Thus, HAdV-mediated expression of IFN-
α has great potential to be developed as a single-dose, fast-
acting therapeutic that can be used to prevent WEEV infection
during a natural outbreak, a bioterrorism attack or a needle stick
accident in the laboratory.
Materials and methods
Cells and viruses
Vero, HEK293 and L929 cells (ATCC) were cultured in
Dulbecco's modified Eagle's media (DMEM) supplemented
with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate,
antibiotics and antimycotics. The WEEV strains of CBA87,
Fleming and 71V-1658 used in this study were described
previously (Nagata et al., 2006). The TC-83 strain of VEEV
(Ludwig et al., 2001) was provided by George Ludwig (the
United States Army Medical Research Institute of Infectious
Diseases, Fort Detrick, MD). To prepare virus stocks, the
original WEEV strains and VEEV TC-83 were passed once in
Vero cells at an MOI of less than 0.1. The titers of the virus
stocks were determined by plaque assay in Vero cells. All the
experiments withWEEV were carried out in the Biosafety Level
3 laboratory at Defence Research and Development Canada –
Suffield (DRDC Suffield) in compliance with guidelines set by
Health Canada and the Canadian Food Inspection Agency. Ad5-
EGFP expressing the EGFP (Wu et al., 2007) was used as a
control.
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The mIFN-α gene was isolated from pORF-mIFNα (Invivo-
Gen) after the digestion of the plasmid with SnaBI and NheI.
The gene was cloned into pCI (Promega) to produce pCI-
mIFNα. A PvuII–XhoI DNA fragment was isolated from pCI-
mIFNα and ligated into EcoRV–XhoI sites in pVAX1
(Invitrogen) to produce pVAX1-mIFNα. A DNA fragment
containing the mIFN-α gene was isolated from pVAX1-mIFNα
after the digestion of the plasmid with HindIII and XbaI. The
fragment was inserted into the compatible sites of pShuttle-
CMV (Qbiogene) to generate a transfer plasmid pSCMV-
mIFNα. The plasmid was linearized by PmeI digestion and co-
transformed with pAdEasy-1 (Qbiogene) into the BJ5183 strain
of Escherichia coli (Qbiogene) to produce an infectious plasmid
pAd5-mIFNα. The plasmid was digested with PacI and
transfected into HEK293 cells by Lipofectamine 2000 (Invitro-
gen) to generate Ad5-mIFNα. Ad5-mIFNα was amplified once
in HEK293 cells, purified by double cesium chloride gradient
centrifugation (Graham and Prevec, 1991), and titrated by the
tissue culture infectious dose 50 (TCID50) assay (Mahy and
Kangro, 1996).
PCR detection of the mIFN-α gene
The viral DNA of Ad5-mIFNα was prepared using DNeasy
Tissue Kits (QIAGEN). The mIFN-α gene was amplified with
primers JQW7 (5′-GGC TAG GCT CTG TGC TTT CC-3′) and
JQW8 (5′-TCA CTC CTC CTT GCT CAA TC-3′). PCR was
carried out by PfuTurbo DNA polymerase (Stratagene) with
2 min of initial denaturation at 95 °C, 30 cycles of 30 s of
denaturing at 94 °C, 30 s of annealing at 55 °C and 1 min of
extension at 70 °C. A final step of 7 min extension at 72 °C was
added after the 30-cycle amplification. As a control, the viral
DNA extracted from Ad5-EGFP was amplified using the same
primers. A 5-μl aliquot of PCR reaction was analyzed by
agarose gel electrophoresis.
Western immunoblot detection of mIFN-α
HEK293 cells seeded in 6-well plates were inoculated with
Ad5-mIFNα at an MOI of 1 in a total of 500 μl of DMEM
supplemented with 2% FBS. Ad5-EGFP-infected HEK293 cells
was used as a control. At 24 h and 48 h after inoculation,
supernatants were collected, boiled for 5 min in a SDS sample
buffer, and loaded onto 12% Bis–Tris SDS polyacrylamide gel
along with a protein standard (Invitrogen) and the recombinant
mIFN-α produced in Escherichia coli (Calbiochem). Proteins
were electrophoresed at 200 V for 1 h, transferred to a
nitrocellulose membrane at 30 V for 2 h and probed with a
rabbit polyclonal antibody specific for mIFN-α (Calbiochem).
In vitro VEEV inhibition assay
L929 cells seeded in 6-well plates were inoculated in
triplicate with Ad5-mIFNα or Ad5-EGFP at an MOI of 5. At
24 h after inoculation, cells were infected with the TC-83 strainof VEEVat an MOI of 0.1 or 0.5. Supernatants were collected at
48 h after the TC-83 infection and the yield of the virus in the
supernatants was determined by plaque assay in Vero cells.
Plaque assay
Supernatants collected from TC-83-infected cells were
serially diluted 10-fold with DMEM containing antibiotics
and antimycotics. Vero cells grown in 6-well plates were
washed once with DMEM and each well was inoculated in
duplicate with 250 μl of the diluted supernatants. The plates
were incubated for 1 h at 37 °C in a 5% CO2 humidified
atmosphere. The inoculated supernatants were removed and
2 ml of overlay (0.6% tragacanth gum, 2% FBS, antibiotics and
antimycotics) was added to each well. At 48 h after incubation,
cells were fixed and stained with Histochoice solution
(Amersco) containing 0.3% crystal violet.
Mouse strain
Female BALB/c mice (17–20 g) were obtained from the
animal care facility at DRDC Suffield. The original breeding
pairs were purchased from Charles River Canada. Protocols of
mouse experiments were prepared according to the guidelines
of the Canadian Council on Animal Care and approved by the
Animal Care Committee of DRDC Suffield.
Measurement of serum mIFN-α
Mice were each injected IM with 107 PFU of Ad5-mIFNα.
At 6 h, 15 h, 24 h, 48 h, 1 week, and 13 weeks after injection,
serum was collected and pooled (6 mice for each time point).
Control mice were each injected with the same dose of Ad5-
EGFP. Serum concentrations of mIFN-α were measured in
triplicate by an ELISA kit (PBL Biomedical Labs) with a
detection limit of 12 pg/ml.
Pre- and post-exposure protection studies
For pre-exposure protection study, mice were each injected
IM with 107 PFU of Ad5-mIFNα or Ad5-EGFP. At 24 h, 48 h,
1 week, and 13 weeks after injection, mice were challenged IN
with various WEEV strains. The detailed procedure for mouse
challenge was described previously (Nagata et al., 2006). In
brief, mice were anaesthetized with sodium pentobarbital and
each mouse was challenged through the nostrils with
1.5×103 PFU of WEEV in 50 μl of Hank's balanced salt
solution. The challenged mice were monitored daily for survival
and the severity of WEEV infection using a scoring system (Wu
et al., 2007). Mice scored at the scale of 4 were terminally ill and
were killed to avoid unnecessary suffering.
For post-exposure protection study, mice were each
challenged IN with 1.5×103 PFU of the Fleming strain of
WEEV. At 6 h after challenge, mice were each injected IM
with 107 PFU of Ad5-mIFNα, 107 PFU of Ad5-EGFP or PBS
and monitored daily for survival and the severity of WEEV
infection.
212 J.Q.H. Wu et al. / Virology 369 (2007) 206–213Statistics
Two-tailed t test was used to determine the statistically
significant difference (Pb0.05) of the TC-83 yield in the VEEV
inhibition study in L929 cells. Two-tailed Fisher's exact test
was used to determine the statistically significant difference
(Pb0.05) of the percentage survival in mice inoculated with
Ad5-mIFNα, Ad5-EGFP or PBS. PRISM 4 program (GraphPad
Software Inc.) was used for statistical analysis.
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